Methods of treating a ras protein-related disease or disorder
AssigneeRevolution Medicines, Inc.
InventorsJingjing JIANG, Mallika SINGH, Zhengping WANG, Zhican WANG, Yu Chi YANG, Lei BAO, Richa DUA
Life of this patent
Estimating the term…
Abstract
The disclosure features methods of treating RAS disorders using Compound A, or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders (e.g., cancer) including combinations of Compound A, or a pharmaceutically acceptable salt thereof, and additional therapeutic agent. Compound A is a compound having the following structure:
Claims51
A method of treating a cancer in a human subject in need thereof, the method comprising orally administering to the subject a total daily dose of 50 mg to 800 mg Compound A:
The method of 30, wherein the additional therapeutic agent is a PD-1 and/or PD-L1 inhibitor.
A method of treating a cancer comprising a RAS G12C mutation in a human subject in need thereof, the method comprising orally administering to the subject a total daily dose of 200 mg to 600 mg of Compound A, wherein Compound A is administered to the subject twice daily.
A method of treating non-small cell lung cancer (NSCLC) comprising a RAS G12C mutation in a human subject in need thereof, the method comprising orally administering to the subject a total daily dose of 200 mg to 600 mg of Compound A, wherein Compound A is administered twice daily.
A method of treating colorectal cancer (CRC) comprising a RAS G12C mutation in a human subject in need thereof, the method comprising orally administering to the subject a total daily dose of 200 mg to 600 mg of Compound A, or a pharmaceutically acceptable salt thereof, wherein Compound A is administered twice daily.
Dependencies are inferred from the claim text.